.png){kind=icon}
.png){kind=icon}
Return
Patient value over patent value: the mandate for open-source oncology
.png){kind=icon}
PRE
AI
B
D
DOI：10.1038/s41571-026-01180-9.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Modern oncology has built highly efficient pathways for patent-protected innovation, but no equivalent machinery for evaluating and developing promising off-patent therapeutics. Herein, we frame ‘open-source oncology’ as a parallel public-interest infrastructure to test, authorize and implement credible generic agents. Designed to translate ownerless evidence into standard-of-care treatments, this framework applies the same scientific seriousness devoted to proprietary drugs, decoupling clinical value from commercial ownership.
Journal
IF:
82.2
Papers:
2.3K
Citations:
3.3W
Organization
Cited Papers